Singapore Clinical Trial: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)

Singapore, April 2 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safet... Read More

Singapore Clinical Trial: DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLOZASIRAN IN ADULTS WITH SEVERE HYPERTRIGLYCERIDEMIA AT HIGH RISK OF ACUTE PANCREATITIS (SHASTA-5 STUDY)

Singapore, April 2 -- The Health Sciences Authority received information related to the study titled 'DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLOZASIRAN ... Read More

Singapore Clinical Trial: A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator’s Choice (IC) in Patients with Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy

Singapore, April 2 -- The Health Sciences Authority received information related to the study titled 'A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Invest... Read More

Singapore Clinical Trial: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician’s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (BLUESTAR-Endometrial01)

Singapore, April 2 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) M... Read More

Singapore Clinical Trial: A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Singapore, April 2 -- The Health Sciences Authority received information related to the study titled 'A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in... Read More

Singapore Clinical Trial: Safety, immunogenicity and efficacy of low dose Nivolumab in adults living with HIV on antiretroviral therapy (ART): NIVO-LD

Singapore, April 2 -- The Health Sciences Authority received information related to the study titled 'Safety, immunogenicity and efficacy of low dose Nivolumab in adults living with HIV on antiretrovi... Read More

Singapore Clinical Trial: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4088044 in Healthy Participants.

Singapore, April 2 -- The Health Sciences Authority received information related to the study titled 'A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study... Read More

Singapore Clinical Trial: Antigen Targeted T cell therapy for Relapsed/Refractory B cell Lymphomas

Singapore, April 2 -- The Health Sciences Authority received information related to the study titled 'Antigen Targeted T cell therapy for Relapsed/Refractory B cell Lymphomas'. The following are the o... Read More

Singapore Clinical Trial: DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer

Singapore, April 2 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig i... Read More

Singapore Clinical Trial: An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BAY 3771249 as monotherapy or combination with other cancer treatments in participants with solid tumors harboring a KRAS G12D mutation

Singapore, April 2 -- The Health Sciences Authority received information related to the study titled 'An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and ... Read More

• ««
• «
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• »
• »»